UK Markets open in 7 hrs 24 mins

Kiromic BioPharma, Inc. (KRBP)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.3070-0.0299 (-8.88%)
At close: 04:00PM EDT
0.3073 +0.00 (+0.10%)
After hours: 04:42PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3N/A
S&P500 52-week change 3N/A
52-week high 311.0000
52-week low 30.2910
50-day moving average 30.6815
200-day moving average 31.7884

Share statistics

Avg vol (3-month) 3360.35k
Avg vol (10-day) 3325.72k
Shares outstanding 515.44M
Implied shares outstanding 6N/A
Float 811.19M
% held by insiders 112.60%
% held by institutions 116.43%
Shares short (28 Apr 2022) 495.35k
Short ratio (28 Apr 2022) 41.33
Short % of float (28 Apr 2022) 40.63%
Short % of shares outstanding (28 Apr 2022) 40.61%
Shares short (prior month 30 Mar 2022) 4198.02k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)30 Dec 2021


Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-72.62%
Return on equity (ttm)-132.30%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -24.84M
Net income avi to common (ttm)-25.81M
Diluted EPS (ttm)-2.2410
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)25.35M
Total cash per share (mrq)1.63
Total debt (mrq)454.5k
Total debt/equity (mrq)1.66
Current ratio (mrq)7.94
Book value per share (mrq)0.66

Cash flow statement

Operating cash flow (ttm)-20.32M
Levered free cash flow (ttm)-12.66M